MovDisordV3, Main, Exploration, bibRecord, 005092

A trial of dextromethorphan in parkinsonian patients with motor response complications

Identifieur interne : 005092 ( Main/Exploration ); précédent : 005091; suivant : 005093

A trial of dextromethorphan in parkinsonian patients with motor response complications

Auteurs : Leo Verhagen Metman [États-Unis] ; Pierre J. Blanchet [États-Unis] ; Pep N Van Den Munckhof [États-Unis] ; Paolo Del Dotto [États-Unis] ; Remco Natté [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1998-05.

RBID : ISTEX:6678D223545AE509A9A53066038F609551C223B3

Descripteurs français

Pascal (Inist)
- Antagoniste, Antiparkinsonien, Chimiothérapie, Dextrométhorphane, Dyskinésie, Homme, Lévodopa, Parkinson maladie, Récepteur NMDA, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Activities of Daily Living (classification), Aged, Antagonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Carbidopa (adverse effects), Carbidopa (therapeutic use), Chemotherapy, Cross-Over Studies, Dextromethorphan, Dextromethorphan (adverse effects), Dextromethorphan (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (drug therapy), Female, Glutamate, Human, Humans, Levodopa, Male, Middle Aged, Motor Skills (drug effects), Motor complications, N-Methylaspartate (antagonists & inhibitors), NMDA, NMDA receptor, Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Treatment.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Dextromethorphan.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- classification : Activities of Daily Living.
- diagnosis : Dyskinesia, Drug-Induced, Parkinson Disease.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Dextromethorphan.
- Aged, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.

Abstract

The effects of the NMDA antagonist dextromethorphan (DM) on levodopa‐associated dyskinesias and motor fluctuations were studied in patients with advanced Parkinson's disease. During initial open‐label dose escalation, 6 of 18 patients reported a beneficial effect at their individually determined optimal DM dose (range, 60–120 mg/day). The 12 remaining patients either experinced reversible side effects, particularly mild drowsiness, or decreased levodopa efficacy, and were therefore excluded from the study. The six responders entered the double‐blind, placebo‐controlled, crossover study with two 2‐week arms separted by 1 week wash‐out. On the last day of each arm, motor ratings were performed every 20 minutes for 8 consecutive hours. In addition, motor complications and Activities of Daily Living (ADL) were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and patient diaries. With DM, dyskinesias improved by 25% according to physician's ratings and by 40% accfording to UPDRS interviews, without compromising the anti‐Parkinson effect of levodopa. Motor fluctuations and ADL scores also improved significantly. Although the narrow therapeutic index of DM limits its clinical usefulness, these findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate levodopa‐associated motor complications.

Url:

https://api.istex.fr/document/6678D223545AE509A9A53066038F609551C223B3/fulltext/pdf

DOI: 10.1002/mds.870130307

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A trial of dextromethorphan in parkinsonian patients with motor response complications</title>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</author>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
</author>
<author><name sortKey="Van Den Munckhof, Pep N" sort="Van Den Munckhof, Pep N" uniqKey="Van Den Munckhof P" first="Pep N" last="Van Den Munckhof">Pep N Van Den Munckhof</name>
</author>
<author><name sortKey="Dotto, Paolo Del" sort="Dotto, Paolo Del" uniqKey="Dotto P" first="Paolo Del" last="Dotto">Paolo Del Dotto</name>
</author>
<author><name sortKey="Natte, Remco" sort="Natte, Remco" uniqKey="Natte R" first="Remco" last="Natté">Remco Natté</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6678D223545AE509A9A53066038F609551C223B3</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130307</idno>
<idno type="url">https://api.istex.fr/document/6678D223545AE509A9A53066038F609551C223B3/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A80</idno>
<idno type="wicri:Area/Istex/Curation">002A80</idno>
<idno type="wicri:Area/Istex/Checkpoint">003828</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Metman L:a:trial:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9613730</idno>
<idno type="wicri:Area/PubMed/Corpus">004431</idno>
<idno type="wicri:Area/PubMed/Curation">004431</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004515</idno>
<idno type="wicri:Area/Ncbi/Merge">004F52</idno>
<idno type="wicri:Area/Ncbi/Curation">004F52</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004F52</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Verhagen Metman L:a:trial:of</idno>
<idno type="wicri:Area/Main/Merge">008005</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:98-0262014</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003037</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003787</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003094</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Metman L:a:trial:of</idno>
<idno type="wicri:Area/Main/Merge">008218</idno>
<idno type="wicri:Area/Main/Curation">005092</idno>
<idno type="wicri:Area/Main/Exploration">005092</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A trial of dextromethorphan in parkinsonian patients with motor response complications</title>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Den Munckhof, Pep N" sort="Van Den Munckhof, Pep N" uniqKey="Van Den Munckhof P" first="Pep N" last="Van Den Munckhof">Pep N Van Den Munckhof</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dotto, Paolo Del" sort="Dotto, Paolo Del" uniqKey="Dotto P" first="Paolo Del" last="Dotto">Paolo Del Dotto</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Natte, Remco" sort="Natte, Remco" uniqKey="Natte R" first="Remco" last="Natté">Remco Natté</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-05">1998-05</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="414">414</biblScope>
<biblScope unit="page" to="417">417</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6678D223545AE509A9A53066038F609551C223B3</idno>
<idno type="DOI">10.1002/mds.870130307</idno>
<idno type="ArticleID">MDS870130307</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term>
<term>Aged</term>
<term>Antagonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Cross-Over Studies</term>
<term>Dextromethorphan</term>
<term>Dextromethorphan (adverse effects)</term>
<term>Dextromethorphan (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Female</term>
<term>Glutamate</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Skills (drug effects)</term>
<term>Motor complications</term>
<term>N-Methylaspartate (antagonists & inhibitors)</term>
<term>NMDA</term>
<term>NMDA receptor</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Dextromethorphan</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Dextromethorphan</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cross-Over Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Dextrométhorphane</term>
<term>Dyskinésie</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Récepteur NMDA</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The effects of the NMDA antagonist dextromethorphan (DM) on levodopa‐associated dyskinesias and motor fluctuations were studied in patients with advanced Parkinson's disease. During initial open‐label dose escalation, 6 of 18 patients reported a beneficial effect at their individually determined optimal DM dose (range, 60–120 mg/day). The 12 remaining patients either experinced reversible side effects, particularly mild drowsiness, or decreased levodopa efficacy, and were therefore excluded from the study. The six responders entered the double‐blind, placebo‐controlled, crossover study with two 2‐week arms separted by 1 week wash‐out. On the last day of each arm, motor ratings were performed every 20 minutes for 8 consecutive hours. In addition, motor complications and Activities of Daily Living (ADL) were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and patient diaries. With DM, dyskinesias improved by 25% according to physician's ratings and by 40% accfording to UPDRS interviews, without compromising the anti‐Parkinson effect of levodopa. Motor fluctuations and ADL scores also improved significantly. Although the narrow therapeutic index of DM limits its clinical usefulness, these findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate levodopa‐associated motor complications.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</region>
<name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Dotto, Paolo Del" sort="Dotto, Paolo Del" uniqKey="Dotto P" first="Paolo Del" last="Dotto">Paolo Del Dotto</name>
<name sortKey="Natte, Remco" sort="Natte, Remco" uniqKey="Natte R" first="Remco" last="Natté">Remco Natté</name>
<name sortKey="Van Den Munckhof, Pep N" sort="Van Den Munckhof, Pep N" uniqKey="Van Den Munckhof P" first="Pep N" last="Van Den Munckhof">Pep N Van Den Munckhof</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005092 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005092 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:6678D223545AE509A9A53066038F609551C223B3
   |texte=   A trial of dextromethorphan in parkinsonian patients with motor response complications
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A trial of dextromethorphan in parkinsonian patients with motor response complications

A trial of dextromethorphan in parkinsonian patients with motor response complications

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.